top of page
![](https://static.wixstatic.com/media/d7ee0c_604145febb6647918438bcaf99b41646~mv2.png/v1/fill/w_96,h_54,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/d7ee0c_604145febb6647918438bcaf99b41646~mv2.png)
For on-target delivery
Whether it's a first-line chemotherapy, a small molecule inhibitor, a protein or genetic material, delivering that drug to the intended target and especially avoiding unintended off-target damage is key to a successful and satisfactory treatment.
​
Oligo Medic has developed a proprietary nanoparticle architecture combining active targeting and stealth to efficiently deliver a wide range of therapeutic payloads, drastically increasing the proportion of drug reaching the intended target.
​
![national-cancer-institute-sIqWYiNLiJU-unsplash.jpg](https://static.wixstatic.com/media/d7ee0c_2a1fff6afe0549d485c4ed9698e44390~mv2.jpg/v1/fill/w_255,h_255,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/national-cancer-institute-sIqWYiNLiJU-unsplash.jpg)
![anthony-tran-rvdlDB1D68c-unsplash.jpg](https://static.wixstatic.com/media/d7ee0c_e3cfc9e6af7244f18018014b8de4963c~mv2.jpg/v1/crop/x_0,y_545,w_2178,h_2178/fill/w_255,h_255,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/anthony-tran-rvdlDB1D68c-unsplash.jpg)
![minimal_technoligs logo-04.png](https://static.wixstatic.com/media/d7ee0c_8cef80e4883e42f09ba45ae88498b742~mv2.png/v1/fill/w_181,h_181,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/minimal_technoligs%20logo-04.png)
bottom of page